


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT

**SINO BIOPHARMACEUTICAL S&P ESG RATING GETS ANOTHER UPGRADE
RANKING TOP 9% IN THE GLOBE**

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**” or “**Sino Biopharmaceutical**”, together with its subsidiaries, the “**Group**”) announces that, according to the 2023 environment, social and governance (“**ESG**”) rating results released by S&P Global Corporate Sustainability Assessment (“**CSA**”), Sino Biopharmaceutical has, for the second consecutive year, achieved an upgrade in rating, which has steadily risen to 55 points, an increase of 10 points as compared to the previous year, ranking top 9% in the globe.

Being one of the global largest annual assessments on implementation of corporate sustainability development, S&P CSA comprehensively reflects the level of ESG management and information disclosure of a company through quantitative scoring of each ESG management item and performance, and is an important base for investment decision-making and data analysis for global investors. In 2023, approximately 350 companies in the pharmaceutical industry were invited to participate in the assessment. The achieved results outperformed 91% of the global peer group for the second consecutive year represents the high recognition from S&P for Sino Biopharmaceutical’s sustainability practices.

In terms of corporate governance, Sino Biopharmaceutical is committed to continuously enhancing the professionalism, independence and diversity of its Board, ensuring stable operation of the company with high-quality corporate governance. In recent years, Sino Biopharmaceutical has adhered to internationalisation and innovation, and continued to increase its investment in independent research and development. At present, the Group has entered the harvesting period of innovation results. In 2022, the net revenue of innovative drugs reached RMB6.75 billion, representing a year-on-year growth of 20%. In the next three years, the Group will have around 10 innovative drugs launched to the market, injecting strong momentum for a long-term sustainable development. In the aspect of risk management, the Group has thoroughly considered and prevented and controlled areas such as ESG and emerging risks, while proactively building a transparent and trustworthy corporate culture.

Sino Biopharmaceutical is insist on international strategy, targets the unsatisfied clinical needs around the globe, and promotes the research and develop of more high quality new drugs and varieties approved and marketed in a synergistic manner between independent research and development and the introduction of innovations from overseas, for the benefit of patients around the world. Meanwhile, the Group promotes the accessibility of medicines in multiple ways. On the one hand, by the improvement of quality and efficiency, patients are provided with high-quality and affordable medicines; on the other hand, the burden of medication on patients is further reduced by holding various public welfare and charitable activities. In the area of talent development, the Group continues to provide excellent work experience to empower employee development and help the enterprise and its employees grow together.

In 2023, Sino Biopharmaceutical was also awarded MSCI ESG A Rating, CCTV's "100 Pioneer China ESG Listed Companies", "2023 Forbes China ESG Innovative Enterprise", "Top 100 Chinese Overseas Listed Companies for ESG and Low Carbon" and other accolades.

In the future, Sino Biopharmaceutical will uphold the concept of sustainable development, continuously integrate ESG concepts with the Group's development strategy, improve risk management, promote sound business growth and create long-term value for shareholders, patients, employees and the community.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 11 December 2023

As at the date of this announcement, the Board of the Company comprises seven executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Tian Zhoushan and Ms. Li Mingqin and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.